Ferrofluid in Medicine: Action Proposal
•Download as PPT, PDF•
1 like•385 views
Within the next 5-7 years, ferrofluids will be safely used to treat and cure diseases like cancer through contributions from NASA, Ferrotec, the FDA, and CDRH, which will allow minimal side effects from cancer treatment and potentially turn cancer into a non-deadly disease within 20 years, though risks like patient allergies and misdirecting the fluid need mitigation through allergy tests and operator training.
Report
Share
Report
Share
![Contributing Agencies ,[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
Orphan Drug Designation
The Office of Orphan Products Development (OOPD) at the FDA promotes the development of treatments for rare diseases and conditions. There are more than 6,800 known rare diseases affecting an estimated 25-30 million Americans. The Orphan Drug Act of 1983 provides financial incentives like tax credits, user fee waivers, and exclusive marketing rights for 7 years to encourage development of treatments for rare diseases. The OOPD oversees programs that grant orphan drug designation, provide funding for clinical trials and natural history studies, and award priority review vouchers for rare pediatric diseases.
The Orphan Drug Act
The document summarizes the Orphan Drug Act of 1983 and its impact. It provides incentives like 7 years of marketing exclusivity and tax credits to stimulate development of drugs for rare diseases defined as affecting fewer than 200,000 people. Since 1983, over 1000 designations and 200 product approvals have occurred. While the Act has met its objectives, concerns around the high costs of orphan drugs and determining appropriate access and reimbursement are discussed.
Ae ppt
This document outlines safety reporting procedures for a clinical trial, including definitions of adverse events and serious adverse events, causality assessment guidelines, reporting timelines, and medical management of adverse events. Adverse events will be monitored for 28 days following vaccination and reported within required timelines. Serious adverse events must be reported within 24 hours of occurrence and followed up until resolution. The ethics committee, regulatory authorities, and sponsor will assess causality and determine compensation if needed.
Mr. janeshwar
The document discusses pharmacovigilance in India, including its history, current challenges, and future goals. It outlines the pharmacovigilance process, including adverse drug reaction reporting procedures. The future of pharmacovigilance in India needs to address issues like increasing awareness, improving reporting rates, and strengthening oversight of medical devices and herbal products. The successful outcome of an effective national pharmacovigilance program would be to improve patient safety, public health, and rational drug use through ongoing monitoring, education, and risk assessment activities.
PAYING FOR BREAKTHROUGH EYE THERAPIES (BIOLOGICS, BIOSIMILARS & GENE THERAPIE...
Presentation by AGTC at OIS@ASRS 2016.
Participant:
Stephen Potter, Chief Business Officer - AGTC
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Drug Safety and Pharmacovigilance - Need for internationally harmonized pape...
Drug Safety and Pharmacovigilance - Need for internationally harmonized pape...Pharmaceutical Compliance Inspection unit, Crown College of Canada
Drug safety and pharmacovigilance need for internationally harmonized paper based spontaneous Adverse Drug Reactions
Dr. Behrouz Mansouri
Dr. Syed Ahmad Ali Shah
Mr. Muhammad Tanvir
Dr. Hafsa Hafeez
Professor Peivand PirouziZuckerman cue june 2012
This document discusses issues with the FDA approval process for medical devices. It notes that over 95% of new medical devices enter the market through the 510(k) premarket notification process, which does not require clinical trials, inspections, or post-market studies to demonstrate safety and efficacy. It cites reports that half a billion 510(k) devices were recalled in 2010-2011 as high risk and that about 15% of regulated devices are ultimately recalled as high or moderate risk. The document argues that clinical trials and other evidence are needed to properly evaluate medical devices and ensure patient safety.
Connecting the Dots for Fast-Track Approval for Rare Disease and Orphan Drug
This document discusses strategies for conducting clinical trials for rare diseases and orphan drugs. It begins with definitions of rare diseases and an overview of legislation related to orphan drugs. It then discusses considerations for site selection, recruitment, study execution, and monitoring that are unique to rare disease trials due to small patient populations and specialized needs. Key approaches include partnering with advocacy groups, using patient registries, minimizing patient burden, and providing tailored training and support to investigators and sites. The goal is to connect patients to trials and facilitate fast-track drug approval to meet significant unmet medical needs.
Recommended
Orphan Drug Designation
The Office of Orphan Products Development (OOPD) at the FDA promotes the development of treatments for rare diseases and conditions. There are more than 6,800 known rare diseases affecting an estimated 25-30 million Americans. The Orphan Drug Act of 1983 provides financial incentives like tax credits, user fee waivers, and exclusive marketing rights for 7 years to encourage development of treatments for rare diseases. The OOPD oversees programs that grant orphan drug designation, provide funding for clinical trials and natural history studies, and award priority review vouchers for rare pediatric diseases.
The Orphan Drug Act
The document summarizes the Orphan Drug Act of 1983 and its impact. It provides incentives like 7 years of marketing exclusivity and tax credits to stimulate development of drugs for rare diseases defined as affecting fewer than 200,000 people. Since 1983, over 1000 designations and 200 product approvals have occurred. While the Act has met its objectives, concerns around the high costs of orphan drugs and determining appropriate access and reimbursement are discussed.
Ae ppt
This document outlines safety reporting procedures for a clinical trial, including definitions of adverse events and serious adverse events, causality assessment guidelines, reporting timelines, and medical management of adverse events. Adverse events will be monitored for 28 days following vaccination and reported within required timelines. Serious adverse events must be reported within 24 hours of occurrence and followed up until resolution. The ethics committee, regulatory authorities, and sponsor will assess causality and determine compensation if needed.
Mr. janeshwar
The document discusses pharmacovigilance in India, including its history, current challenges, and future goals. It outlines the pharmacovigilance process, including adverse drug reaction reporting procedures. The future of pharmacovigilance in India needs to address issues like increasing awareness, improving reporting rates, and strengthening oversight of medical devices and herbal products. The successful outcome of an effective national pharmacovigilance program would be to improve patient safety, public health, and rational drug use through ongoing monitoring, education, and risk assessment activities.
PAYING FOR BREAKTHROUGH EYE THERAPIES (BIOLOGICS, BIOSIMILARS & GENE THERAPIE...
Presentation by AGTC at OIS@ASRS 2016.
Participant:
Stephen Potter, Chief Business Officer - AGTC
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Drug Safety and Pharmacovigilance - Need for internationally harmonized pape...
Drug Safety and Pharmacovigilance - Need for internationally harmonized pape...Pharmaceutical Compliance Inspection unit, Crown College of Canada
Drug safety and pharmacovigilance need for internationally harmonized paper based spontaneous Adverse Drug Reactions
Dr. Behrouz Mansouri
Dr. Syed Ahmad Ali Shah
Mr. Muhammad Tanvir
Dr. Hafsa Hafeez
Professor Peivand PirouziZuckerman cue june 2012
This document discusses issues with the FDA approval process for medical devices. It notes that over 95% of new medical devices enter the market through the 510(k) premarket notification process, which does not require clinical trials, inspections, or post-market studies to demonstrate safety and efficacy. It cites reports that half a billion 510(k) devices were recalled in 2010-2011 as high risk and that about 15% of regulated devices are ultimately recalled as high or moderate risk. The document argues that clinical trials and other evidence are needed to properly evaluate medical devices and ensure patient safety.
Connecting the Dots for Fast-Track Approval for Rare Disease and Orphan Drug
This document discusses strategies for conducting clinical trials for rare diseases and orphan drugs. It begins with definitions of rare diseases and an overview of legislation related to orphan drugs. It then discusses considerations for site selection, recruitment, study execution, and monitoring that are unique to rare disease trials due to small patient populations and specialized needs. Key approaches include partnering with advocacy groups, using patient registries, minimizing patient burden, and providing tailored training and support to investigators and sites. The goal is to connect patients to trials and facilitate fast-track drug approval to meet significant unmet medical needs.
Pharmacovigilance Process Work Flow - Katalyst HLS
Introduction to Drug Safety & Pharmacovigilance Process Work Flow for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Brand vs Generic -A War?
This document discusses generics versus brand name anti-epileptic drugs (AEDs). It notes that generics have the same active ingredients and biological effects as brand names, but some concerns exist regarding their approval process and effects on certain populations like children and the elderly. While regulatory agencies say existing bioequivalence rules are adequate, both they and patient advocacy groups may be biased. The document concludes there is reason for concern about current generic regulations and advises doctors to track what medications patients receive and educate others to minimize risks of substituting generics.
Orphan Drugs
This presentation will gives you a brief idea about Orphan Diseases, Orphan Drugs, the Orphan Drug Act (ODA), and Incentives and Impact of ODA
RyMat Inc.: A Look At Generic vs. Brand Pharmaceuticals
The document discusses generics vs brand name drugs and risks associated with generics. It notes that generics must have the same active ingredients and be within 10-25% of brand name drug concentrations to be approved. However, generics may have different inactive ingredients and manufacturing processes can vary, resulting in differences between generics. The document outlines issues found at some generic drug manufacturing plants in India and China, including falsifying data, poor quality control, and hiding failed test results. It warns that not all generics are equal and some imported from these countries may pose risks.
Fda adverse event reporting requirements for otc drugs
ComplianceOnline webinar on regulatory requirements for adverse event reporting for dietary supplements and OTC products
Pharmacovigilance Training in Oracle Argus Safety Database
Pharmacovigilance training is essential for pharmaceutical and healthcare organizations to ensure your operations comply with the latest regulatory guidelines, laws and standards. At Gratisol Labs, we provide industry-leading pharmacovigilance training courses with hands on experience on safety databases & medical coding that cover the basics of Pharmacovigilance till advanced drug safety topics, the regulatory requirements of pharmacovigilance, signal detection, and pharmacovigilance audits are covered in the complete Gratisol Labs Pharmacovigilance Training Programme.
Emily Qian, "Physician-Mediated Elective Whole Genome Sequencing Tests"
Emily Qian, "Physician-Mediated Elective Whole Genome Sequencing Tests"The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
May 17, 2019
Breakthroughs in genetics have often raised complex ethical and legal questions, which loom ever larger as genetic testing is becoming more commonplace, affordable, and comprehensive and genetic editing becomes poised to be a consumer technology. As genetic technologies become more accessible to individuals, the ethical and legal questions around the consumer use of these technologies become more pressing.
As these questions become more pressing, now is the time to re-consider what ethical and regulatory safeguards should be implemented and discuss the many questions raised by advancements in consumer genetics.
Presentation: Emily Qian, Genetic Counselor, Veritas Genetics (with Magalie Leduc, Rebecca Hodges, Bryan Cosca, Ryan Durigan, Laurie McCright, Doug Flood, and Birgit Funke) - Physician-Mediated Elective Whole Genome Sequencing Tests: Impacts on Informed Consent
Learn more: https://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conferenceWhat is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...Canadian Cancer Survivor Network
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Discussion on biologics, including an explanation of the high level of precision that is required to produce a consistent biological product each time.
● Discussion on the growing interest in biosimilars, followed by what we can learn from Europe’s experience.
● Health Canada’s position on biosimilars, discussion on key issues surrounding biosimilars relevant to the Canadian market.
● The importance of patient safety and patient choice.
View the video: https://youtu.be/h3Ap6HoiSC8
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/SurvivornetcaAdr reporting ppt
The document discusses adverse drug reaction (ADR) reporting tools. It provides a brief history of pharmacovigilance and describes the ADR reporting process from healthcare professionals to regional and zonal centers, and finally to national and global databases. It emphasizes the importance of post-marketing ADR monitoring to identify uncommon or rare reactions not detected during clinical trials. Key aspects like what information to report, who can report, and how to submit reports using standardized forms are summarized. Common ADR reporting software tools like Argus are also highlighted.
Pv overview (2)
The document discusses the history and importance of pharmacovigilance in ensuring drug safety. It describes how the thalidomide tragedy in the 1960s demonstrated the need for rigorous post-approval drug safety monitoring. Key aspects of pharmacovigilance include detecting, assessing, and preventing adverse drug reactions through methods like spontaneous reporting of suspected reactions. Causality assessment is important to determine if a reaction is truly associated with a drug. Regulatory agencies and organizations like the WHO play important roles in pharmacovigilance systems globally.
Introduction to Pharmacovigilance| B- PHARM| PHARMACOVIGILANCE
Pharmacovigilance involves monitoring medical substances to watch for adverse effects. It aims to understand drug safety risks and effectiveness based on evidence beyond clinical trials. Pharmacovigilance classifies adverse drug reactions and assesses causality between drugs and adverse events to enhance public health. Adverse drug reactions are unintended harmful responses to drugs, while adverse drug events may lack identified causality. Multiple sources can report adverse events to further pharmacovigilance activities.
Day 1:11:00am-12:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1:11:00am-12:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019Canadian Organization for Rare Disorders
The document discusses genome-wide sequencing for diagnosis of rare diseases in Canada. It notes the current unmet clinical need, with specialists taking 3-5 years on average to diagnose rare diseases and 40% of patients receiving more than 3 misdiagnoses. Access to clinical exome sequencing varies across Canada. The goal of the Partnership discussed is to ensure access to clinical genome-wide sequencing as standard of care for Canadians at risk for a serious genetic condition who would benefit from timely diagnosis and intervention. It will include access to sequencing, data governance, a pan-Canadian data ecosystem for sharing to catalyze innovation, engagement of patients/communities and health professionals, and establishment of a rare disease cohort and diagnostic ecosystem to scale data.Pharmacovigilance
Pharmacovigilance is the science of monitoring the effects of medicines to identify new information about drug safety and potential adverse effects. It aims to improve patient care, public health, and understanding of medication risks. Pharmacovigilance systems work to detect, assess, and prevent adverse drug reactions through alert watchfulness, careful reporting of side effects and medication errors, and implementing interventions to promote safer drug use and adherence. While clinical trials provide some safety information, pharmacovigilance is still needed after approval due to limitations of pre-market research and individual variability in drug responses.
Dean Baker Selling Sickness 2010
The document summarizes problems with the current pharmaceutical patent system and incentives it creates, and proposes publicly funding research and medical education instead. Key issues with patents include inefficient drug use and costs, focus on profitable treatments over needs, and distortions in research, education, and marketing. The proposal involves long-term master contracts totaling $30-40 billion annually for public research, requiring all results be openly shared online, and educating doctors with no drug company influence to improve priorities and transparency.
Pharma cost
This document discusses the high costs of pharmaceuticals. It notes that regulatory agencies like the FDA and ICH oversee medication safety and the research and development process, which can take 10-20 years and costs over $1 billion. The drug development process involves testing thousands of potential drugs in animals and humans, with only 1 ultimately being approved. These extensive research and testing requirements, along with the costs of clinical trials, equipment, and staff salaries contribute significantly to the high prices of medications.
The Dark Side of Pharma Globalization
U.S. dependency on foreign pharmaceutical production imposes vulnerability to failure
Authors: Veronika Valdova, D.V.M. and Ronald L Sheckler
Affiliation: Arete-Zoe, LLC
ABSTRACT
Pharmaceutical supply chains have become increasingly complex due to the shift of manufacturing and critical operations to Asia. U.S. pharmaceutical dependency on foreign sole-source production of essential materials imposes vulnerability affecting the entire industry and national health systems from interruption by exposure to natural events and man-made threats, both accidental and criminal as well as political. Sector vulnerabilities stem from complex regulatory landscape, difficulties for enforcement of quality standards at foreign facilities, single-source supply chain resulting from limited sourcing options, increasing shipping distance exposure to both natural events and complicated by maritime chokepoints. Periodic and chronic shortages of many essential products across therapeutic categories have been significant for more than a decade. The Covid-19 crisis aggravated some of these long-standing issues and made the systemic vulnerabilities publicly evident. The combination of limited capacity to exercise control over essential commodities, the long-term trend of outsourcing, with the politicization of business relationships causes the entire pharmaceutical industrial sector to be internationally dependent, creating numerous potentials for systemic failure.
Pharmacovigilance: An umbrella word for DRug safety.
In this PPT All type of information regarding pharmacovigilance is to be given. i hope this will give your answers regarding p'covigilance.
Marketing in the Healthcare Sector
This document discusses hospital-acquired infections, specifically MRSA, and compares Johns Hopkins Hospital and Hospital of the University of Pennsylvania. It provides details on the history, facilities, specialties, and infection rates of each hospital. Johns Hopkins has nearly 1,000 physicians across 17 departments and occupies 20 buildings on its campus. The University of Pennsylvania includes its medical school and operates 3 hospitals as part of its health system campus. Both hospitals have strong reputations for research and ranked highly by US News, but Johns Hopkins had lower infection rates than national averages in 2011.
Pharmacovigilance
This gives you a basic role pharmacovigilance and how it works before and after drug approval .It totally work for human needs.And what are governing bodies for pharmacovigilance and how to write Adverse Drug Reaction (ADR) Reporting Procedure.
Pharmacovigilance and adr
The document discusses pharmacovigilance and adverse drug reactions (ADRs). It provides historical context on important events that increased focus on pharmacovigilance like the Thalidomide disaster. It describes the need for pharmacovigilance due to limitations of preclinical and clinical trials. It outlines the aims, methods like spontaneous reporting and causality assessment, and programs in India and by the WHO. It defines ADRs and provides classifications. In summary, the document overviews the importance and process of pharmacovigilance in monitoring drug safety post marketing.
Understanding pharmacovigilance
Pharmacovigilance is the science of monitoring the safety of medicines. It involves detecting, assessing, understanding, and preventing adverse effects of drugs. Pharmacovigilance activities begin during clinical trials and continue throughout a product's lifecycle. The goal of pharmacovigilance is to improve patient safety, public health, and understanding of medication risks and benefits. Careers in pharmacovigilance include roles monitoring adverse events, assessing drug safety, and reviewing medical information to evaluate safety profiles.
Orphan drugs
This document discusses orphan drugs, which treat rare diseases. It defines orphan drugs and outlines criteria used in the US and EU to designate drugs for rare diseases. Rare diseases affect fewer than 200,000 people in the US and 10,000 in the EU. The Orphan Drug Act of 1983 in the US provided incentives for orphan drug development. Similar laws exist in other countries. Developing orphan drugs is challenging due to low patient populations and high costs. Examples of orphan drugs and their manufacturers are provided. The process for obtaining orphan drug designation is also summarized.
More Related Content
What's hot
Pharmacovigilance Process Work Flow - Katalyst HLS
Introduction to Drug Safety & Pharmacovigilance Process Work Flow for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Brand vs Generic -A War?
This document discusses generics versus brand name anti-epileptic drugs (AEDs). It notes that generics have the same active ingredients and biological effects as brand names, but some concerns exist regarding their approval process and effects on certain populations like children and the elderly. While regulatory agencies say existing bioequivalence rules are adequate, both they and patient advocacy groups may be biased. The document concludes there is reason for concern about current generic regulations and advises doctors to track what medications patients receive and educate others to minimize risks of substituting generics.
Orphan Drugs
This presentation will gives you a brief idea about Orphan Diseases, Orphan Drugs, the Orphan Drug Act (ODA), and Incentives and Impact of ODA
RyMat Inc.: A Look At Generic vs. Brand Pharmaceuticals
The document discusses generics vs brand name drugs and risks associated with generics. It notes that generics must have the same active ingredients and be within 10-25% of brand name drug concentrations to be approved. However, generics may have different inactive ingredients and manufacturing processes can vary, resulting in differences between generics. The document outlines issues found at some generic drug manufacturing plants in India and China, including falsifying data, poor quality control, and hiding failed test results. It warns that not all generics are equal and some imported from these countries may pose risks.
Fda adverse event reporting requirements for otc drugs
ComplianceOnline webinar on regulatory requirements for adverse event reporting for dietary supplements and OTC products
Pharmacovigilance Training in Oracle Argus Safety Database
Pharmacovigilance training is essential for pharmaceutical and healthcare organizations to ensure your operations comply with the latest regulatory guidelines, laws and standards. At Gratisol Labs, we provide industry-leading pharmacovigilance training courses with hands on experience on safety databases & medical coding that cover the basics of Pharmacovigilance till advanced drug safety topics, the regulatory requirements of pharmacovigilance, signal detection, and pharmacovigilance audits are covered in the complete Gratisol Labs Pharmacovigilance Training Programme.
Emily Qian, "Physician-Mediated Elective Whole Genome Sequencing Tests"
Emily Qian, "Physician-Mediated Elective Whole Genome Sequencing Tests"The Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics
May 17, 2019
Breakthroughs in genetics have often raised complex ethical and legal questions, which loom ever larger as genetic testing is becoming more commonplace, affordable, and comprehensive and genetic editing becomes poised to be a consumer technology. As genetic technologies become more accessible to individuals, the ethical and legal questions around the consumer use of these technologies become more pressing.
As these questions become more pressing, now is the time to re-consider what ethical and regulatory safeguards should be implemented and discuss the many questions raised by advancements in consumer genetics.
Presentation: Emily Qian, Genetic Counselor, Veritas Genetics (with Magalie Leduc, Rebecca Hodges, Bryan Cosca, Ryan Durigan, Laurie McCright, Doug Flood, and Birgit Funke) - Physician-Mediated Elective Whole Genome Sequencing Tests: Impacts on Informed Consent
Learn more: https://petrieflom.law.harvard.edu/events/details/2019-petrie-flom-center-annual-conferenceWhat is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...Canadian Cancer Survivor Network
Please share this slideshow with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Discussion on biologics, including an explanation of the high level of precision that is required to produce a consistent biological product each time.
● Discussion on the growing interest in biosimilars, followed by what we can learn from Europe’s experience.
● Health Canada’s position on biosimilars, discussion on key issues surrounding biosimilars relevant to the Canadian market.
● The importance of patient safety and patient choice.
View the video: https://youtu.be/h3Ap6HoiSC8
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/SurvivornetcaAdr reporting ppt
The document discusses adverse drug reaction (ADR) reporting tools. It provides a brief history of pharmacovigilance and describes the ADR reporting process from healthcare professionals to regional and zonal centers, and finally to national and global databases. It emphasizes the importance of post-marketing ADR monitoring to identify uncommon or rare reactions not detected during clinical trials. Key aspects like what information to report, who can report, and how to submit reports using standardized forms are summarized. Common ADR reporting software tools like Argus are also highlighted.
Pv overview (2)
The document discusses the history and importance of pharmacovigilance in ensuring drug safety. It describes how the thalidomide tragedy in the 1960s demonstrated the need for rigorous post-approval drug safety monitoring. Key aspects of pharmacovigilance include detecting, assessing, and preventing adverse drug reactions through methods like spontaneous reporting of suspected reactions. Causality assessment is important to determine if a reaction is truly associated with a drug. Regulatory agencies and organizations like the WHO play important roles in pharmacovigilance systems globally.
Introduction to Pharmacovigilance| B- PHARM| PHARMACOVIGILANCE
Pharmacovigilance involves monitoring medical substances to watch for adverse effects. It aims to understand drug safety risks and effectiveness based on evidence beyond clinical trials. Pharmacovigilance classifies adverse drug reactions and assesses causality between drugs and adverse events to enhance public health. Adverse drug reactions are unintended harmful responses to drugs, while adverse drug events may lack identified causality. Multiple sources can report adverse events to further pharmacovigilance activities.
Day 1:11:00am-12:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1:11:00am-12:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019Canadian Organization for Rare Disorders
The document discusses genome-wide sequencing for diagnosis of rare diseases in Canada. It notes the current unmet clinical need, with specialists taking 3-5 years on average to diagnose rare diseases and 40% of patients receiving more than 3 misdiagnoses. Access to clinical exome sequencing varies across Canada. The goal of the Partnership discussed is to ensure access to clinical genome-wide sequencing as standard of care for Canadians at risk for a serious genetic condition who would benefit from timely diagnosis and intervention. It will include access to sequencing, data governance, a pan-Canadian data ecosystem for sharing to catalyze innovation, engagement of patients/communities and health professionals, and establishment of a rare disease cohort and diagnostic ecosystem to scale data.Pharmacovigilance
Pharmacovigilance is the science of monitoring the effects of medicines to identify new information about drug safety and potential adverse effects. It aims to improve patient care, public health, and understanding of medication risks. Pharmacovigilance systems work to detect, assess, and prevent adverse drug reactions through alert watchfulness, careful reporting of side effects and medication errors, and implementing interventions to promote safer drug use and adherence. While clinical trials provide some safety information, pharmacovigilance is still needed after approval due to limitations of pre-market research and individual variability in drug responses.
Dean Baker Selling Sickness 2010
The document summarizes problems with the current pharmaceutical patent system and incentives it creates, and proposes publicly funding research and medical education instead. Key issues with patents include inefficient drug use and costs, focus on profitable treatments over needs, and distortions in research, education, and marketing. The proposal involves long-term master contracts totaling $30-40 billion annually for public research, requiring all results be openly shared online, and educating doctors with no drug company influence to improve priorities and transparency.
Pharma cost
This document discusses the high costs of pharmaceuticals. It notes that regulatory agencies like the FDA and ICH oversee medication safety and the research and development process, which can take 10-20 years and costs over $1 billion. The drug development process involves testing thousands of potential drugs in animals and humans, with only 1 ultimately being approved. These extensive research and testing requirements, along with the costs of clinical trials, equipment, and staff salaries contribute significantly to the high prices of medications.
The Dark Side of Pharma Globalization
U.S. dependency on foreign pharmaceutical production imposes vulnerability to failure
Authors: Veronika Valdova, D.V.M. and Ronald L Sheckler
Affiliation: Arete-Zoe, LLC
ABSTRACT
Pharmaceutical supply chains have become increasingly complex due to the shift of manufacturing and critical operations to Asia. U.S. pharmaceutical dependency on foreign sole-source production of essential materials imposes vulnerability affecting the entire industry and national health systems from interruption by exposure to natural events and man-made threats, both accidental and criminal as well as political. Sector vulnerabilities stem from complex regulatory landscape, difficulties for enforcement of quality standards at foreign facilities, single-source supply chain resulting from limited sourcing options, increasing shipping distance exposure to both natural events and complicated by maritime chokepoints. Periodic and chronic shortages of many essential products across therapeutic categories have been significant for more than a decade. The Covid-19 crisis aggravated some of these long-standing issues and made the systemic vulnerabilities publicly evident. The combination of limited capacity to exercise control over essential commodities, the long-term trend of outsourcing, with the politicization of business relationships causes the entire pharmaceutical industrial sector to be internationally dependent, creating numerous potentials for systemic failure.
Pharmacovigilance: An umbrella word for DRug safety.
In this PPT All type of information regarding pharmacovigilance is to be given. i hope this will give your answers regarding p'covigilance.
Marketing in the Healthcare Sector
This document discusses hospital-acquired infections, specifically MRSA, and compares Johns Hopkins Hospital and Hospital of the University of Pennsylvania. It provides details on the history, facilities, specialties, and infection rates of each hospital. Johns Hopkins has nearly 1,000 physicians across 17 departments and occupies 20 buildings on its campus. The University of Pennsylvania includes its medical school and operates 3 hospitals as part of its health system campus. Both hospitals have strong reputations for research and ranked highly by US News, but Johns Hopkins had lower infection rates than national averages in 2011.
Pharmacovigilance
This gives you a basic role pharmacovigilance and how it works before and after drug approval .It totally work for human needs.And what are governing bodies for pharmacovigilance and how to write Adverse Drug Reaction (ADR) Reporting Procedure.
Pharmacovigilance and adr
The document discusses pharmacovigilance and adverse drug reactions (ADRs). It provides historical context on important events that increased focus on pharmacovigilance like the Thalidomide disaster. It describes the need for pharmacovigilance due to limitations of preclinical and clinical trials. It outlines the aims, methods like spontaneous reporting and causality assessment, and programs in India and by the WHO. It defines ADRs and provides classifications. In summary, the document overviews the importance and process of pharmacovigilance in monitoring drug safety post marketing.
What's hot (20)
Pharmacovigilance Process Work Flow - Katalyst HLS
Pharmacovigilance Process Work Flow - Katalyst HLS
RyMat Inc.: A Look At Generic vs. Brand Pharmaceuticals
RyMat Inc.: A Look At Generic vs. Brand Pharmaceuticals
Fda adverse event reporting requirements for otc drugs
Fda adverse event reporting requirements for otc drugs
Pharmacovigilance Training in Oracle Argus Safety Database
Pharmacovigilance Training in Oracle Argus Safety Database
Emily Qian, "Physician-Mediated Elective Whole Genome Sequencing Tests"
Emily Qian, "Physician-Mediated Elective Whole Genome Sequencing Tests"
What is a biosimilar? All you need to know about the current biologics and bi...
What is a biosimilar? All you need to know about the current biologics and bi...
Introduction to Pharmacovigilance| B- PHARM| PHARMACOVIGILANCE
Introduction to Pharmacovigilance| B- PHARM| PHARMACOVIGILANCE
Day 1:11:00am-12:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Day 1:11:00am-12:00pm Panel Slides (Nov 18) Access to Innovation Conference 2019
Pharmacovigilance: An umbrella word for DRug safety.
Pharmacovigilance: An umbrella word for DRug safety.
Similar to Ferrofluid in Medicine: Action Proposal
Understanding pharmacovigilance
Pharmacovigilance is the science of monitoring the safety of medicines. It involves detecting, assessing, understanding, and preventing adverse effects of drugs. Pharmacovigilance activities begin during clinical trials and continue throughout a product's lifecycle. The goal of pharmacovigilance is to improve patient safety, public health, and understanding of medication risks and benefits. Careers in pharmacovigilance include roles monitoring adverse events, assessing drug safety, and reviewing medical information to evaluate safety profiles.
Orphan drugs
This document discusses orphan drugs, which treat rare diseases. It defines orphan drugs and outlines criteria used in the US and EU to designate drugs for rare diseases. Rare diseases affect fewer than 200,000 people in the US and 10,000 in the EU. The Orphan Drug Act of 1983 in the US provided incentives for orphan drug development. Similar laws exist in other countries. Developing orphan drugs is challenging due to low patient populations and high costs. Examples of orphan drugs and their manufacturers are provided. The process for obtaining orphan drug designation is also summarized.
Class clinical pharmacology
This document discusses evidence-based medicine and the process of conducting clinical trials to evaluate new drugs. It describes how clinical trials progress from early phases evaluating safety and appropriate dosing to later phases assessing efficacy. Key aspects addressed include study design, informed consent, ethics review, and post-marketing surveillance. The goal of drug development is to demonstrate that a new medication has genuine clinical benefit compared to existing options and that its risks are closely monitored.
PDPT Webcast - Part 2 - Using Patient Delivered Partner Therapy
This document discusses using patient delivered partner therapy (PDPT) to manage sexual partners of patients diagnosed with chlamydia or gonorrhea. PDPT involves providing patients antibiotics or prescriptions to give to partners who may not seek treatment. The document outlines California laws allowing PDPT for chlamydia and gonorrhea, recommended antibiotics, guidelines for using PDPT, educating partners, and resources for implementation.
Drugs for rare diseases, Orphan Drugs
This document discusses drugs for rare diseases. It begins by defining rare diseases according to different organizations. Rare diseases are individually rare but collectively common, affecting around 6-8% of the global population. Developing drugs for rare diseases is challenging due to the small patient populations and high costs. Governments provide incentives like tax breaks and exclusive rights to encourage pharmaceutical companies to develop orphan drugs. Recent advances in genetics have helped identify causes of many rare diseases and accelerated drug development. While treatment options have increased in recent decades, more understanding and viable treatments are still needed for most rare diseases.
Pharmacovigilance - an introduction
Pharmacovigilance is the science of monitoring the safety of medicines. It plays a key role in identifying adverse drug reactions and preventing harm to patients. The goal of pharmacovigilance is to monitor drug safety, identify health risks, and prevent harm through careful tracking of side effects from clinical trials through a drug's entire lifecycle on the market. Major organizations like the FDA, EMEA, and WHO work to coordinate pharmacovigilance efforts internationally and protect public health.
Pharmacovigilance
This document discusses pharmacovigilance, which involves monitoring the safety of drugs after they have been approved. It defines pharmacovigilance and explains why it is needed given limitations of clinical trials. It describes types of adverse drug reactions and how they are classified. It outlines the goals and processes of pharmacovigilance programs, including reporting adverse reactions, conducting causality assessments, and submitting periodic safety update reports. The overall aim is to ensure safe and effective use of medicines through continual monitoring and regulatory action.
Pharmacovigilance
it is a presentation about Pharmacovigilance, what is? what is the basic information about it? what should I Know as a pharmacy student?
Adverse Drug Reactions.pptx
The document discusses adverse drug reactions (ADRs), including definitions, classifications, reporting and management. Some key points:
- ADRs occur in 5-10% of patients annually. An ADR is an unintended reaction to a drug that occurs at normal doses.
- Serious ADRs result in death, hospitalization, disability or birth defects. Suspected ADRs have a reasonable possibility of being caused by a drug.
- ADRs can be classified based on dose (augmented, bizarre), time (early, late), or susceptibility (gender, age, genetics).
- Healthcare providers should report all suspected ADRs to monitoring centers to identify safety issues. Prevention
Evolving Switch Strategies for Virologically Suppressed HIV-Infected Patients...
Доктор David A. Wohl при участии группы экспертов, рассматривает основные исследования о том, когда и как, при каких условиях переводить пациентов со стабильной супрессией ВИЧ на новые методы лечения .
Generic versus brand antiepileptic drugs keppra
The document discusses the risks and considerations around generic substitution of brand name antiepileptic drugs. It notes that while generics may reduce costs, generic AEDs may not be therapeutically equivalent to the brand name versions due to differences in bioavailability and potential problems from changes in drug levels. The document recommends against substituting brand AEDs with generics, especially for patients with well-controlled epilepsy, due to the serious risks of seizure recurrence or increased side effects from changes in drug concentrations.
Pharmacovigilance, its importance, objectives and assessment
Pharmacovigilance, its importance, objectives and assessment
Dostarlimab as an Anticancer
Dostarlimab JEMPERLI is a PD 1 monoclonal antibody for the treatment of adult patients, with mismatch repair deficient dMMR , recurrent or advanced endometrial cancer that has progressed on or following prior therapy with a platinum containing regimen. As determined by an FDA approved test this indication was granted rapid approval based on the rate of tumor response and the duration of the response. Continued approval for this indication is conditioned on further confirmatory trials demonstrating and documenting clinical benefit. In June 2022, the clinical trial NCT04165772 reported a 100 remission rate for rectal cancer. This clinical trial brought proof that we can match a tumor and the genetics of what is driving it, with therapy. This clinical trial continues to enroll patient and is currently enrolling patients with gastric, prostate, and pancreatic cancers. Dostarlamib is being recommended for rectal cancer. The focus of this review is to summarize the existing knowledge regarding Dostarlimab and explore the possibilities of mono and combination therapies. Tanuja Shaikh | Snehal Pawar | Mr. Arpit Rajaram Suralkar "Dostarlimab as an Anticancer" Published in International Journal of Trend in Scientific Research and Development (ijtsrd), ISSN: 2456-6470, Volume-6 | Issue-6 , October 2022, URL: https://www.ijtsrd.com/papers/ijtsrd52167.pdf Paper URL: https://www.ijtsrd.com/pharmacy/pharmacology-/52167/dostarlimab-as-an-anticancer/tanuja-shaikh
pharmacovigilance-111031093044-phpapp01.pdf
This document discusses pharmacovigilance, which is the science of detecting adverse effects of medications. It defines key terms like adverse drug reactions and side effects. The aims of pharmacovigilance are to improve patient safety, public health, and understanding of medication risks and benefits. Serious adverse reactions that should be reported include death, life-threatening events, hospitalization, and birth defects. Adverse reactions can be caused by intrinsic drug factors or extrinsic factors like interactions. Pharmacovigilance systems help record, analyze, and prevent medication errors to promote safer use of drugs.
Pharmacovigilance by bishnu koirala
Pharmacovigilance is the science of monitoring the safety of medicines. It aims to detect adverse effects from drugs, understand their causes, and prevent patient harm. Pharmacovigilance programs collect reports of adverse drug reactions and analyze the data to identify safety issues, quantify risks, and communicate safety information to patients and healthcare professionals. The ultimate goals are to protect patients and promote the safe use of medicines.
Evolution of Medications
This document discusses the evolution and regulation of medicinal drugs. It covers the major areas of pharmacology, terminology used in drug development and use, substances that have changed medicine, reasons for medication use, routes of drug administration, sources of drugs and their effects, legislation around controlled substances, the phases of clinical drug trials, and FDA regulation including pregnancy risk categories.
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...
The document summarizes highlights from the 7th IAS Conference on HIV Pathogenesis, Treatment, and Prevention held in Kuala Lumpur, Malaysia in June-July 2013. Key findings included the WHO updating treatment guidelines to recommend initiating ART at CD4 counts ≤500 cells/mm3 and preferring TDF+3TC(FTC)+EFV as the initial regimen. Studies found noninferiority of 400mg EFV and demonstrated the efficacy of second-line LPV/r-based ART and PrEP with TDF in specific populations. Adherence to treatment was an important factor in outcomes.
Rational drug, Essential drugs.pptx
This document discusses rational drug use, essential drugs, fixed dose combinations (FDCs), over-the-counter (OTC) drugs, orphan drugs, and fast-track drug designation. It defines these terms and outlines their advantages and disadvantages. Rational drug use refers to using the appropriate drug, dose, form, route and cost for the right patient and diagnosis. Essential drugs are those necessary to address a population's health needs. Orphan drugs are treatments for rare diseases affecting less than 1% of the population. OTC drugs can be used safely without a prescription for minor conditions.
Spontaneous Reporting and Prescription Event Monitoring.pptx
This document discusses pharmacovigilance and post-marketing drug safety monitoring. It defines key terms like adverse drug reaction and signal. It explains limitations of pre-approval clinical trials in detecting all ADRs. Various pharmacovigilance strategies are outlined like spontaneous reporting, prescription event monitoring, and case studies. Reporting procedures and timelines are provided. The national pharmacovigilance program in India is described with its structure and operations. Benefits and limitations of spontaneous reporting are highlighted. Prescription event monitoring is explained as a form of post-marketing surveillance.
Pharmacovigilance in Focus by Dr.Prashant, Cipla
The document discusses pharmacovigilance and medicine safety. It outlines some of the causes of adverse drug reactions including misuse, human error, and inherent drug safety issues. It provides statistics on the prevalence and economic impact of adverse drug reactions. It discusses key events that shaped pharmacovigilance like the Thalidomide tragedy and issues with Vioxx. It also covers regulatory responses and challenges in pharmacovigilance.
Similar to Ferrofluid in Medicine: Action Proposal (20)
PDPT Webcast - Part 2 - Using Patient Delivered Partner Therapy
PDPT Webcast - Part 2 - Using Patient Delivered Partner Therapy
Evolving Switch Strategies for Virologically Suppressed HIV-Infected Patients...
Evolving Switch Strategies for Virologically Suppressed HIV-Infected Patients...
Pharmacovigilance, its importance, objectives and assessment
Pharmacovigilance, its importance, objectives and assessment
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...
Highlights of IAS 2013.CCO Official Conference Coverage of the 7th IAS Confer...
Spontaneous Reporting and Prescription Event Monitoring.pptx
Spontaneous Reporting and Prescription Event Monitoring.pptx
Ferrofluid in Medicine: Action Proposal
- 1. Action Proposal: Biomedical Use of Ferrofluids In the next five to seven years ferrofluid will safety be used to help cure or heal a variety of diseases, the most important being cancer.